Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: A systematic review and meta-analysis 11 Medical and Health Sciences 1117 Public Health and Health Services

Giovanni Sotgiu, Stefano Aliberti, Andrea Gramegna, Marco Mantero, Marta Di Pasquale, Federica Trogu, Laura Saderi, Francesco Blasi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Pneumonia is a relevant clinical and public health issue worldwide frequently associated with infections caused by Multi-Drug Resistant (MDR) pathogens. Ceftaroline fosamil is a promising new antibiotics with broad-spectrum bacterial activity. The aim of this systematic review and meta-analysis is to assess the efficacy and the effectiveness of ceftaroline fosamil in community-acquired (CAP), hospital-acquired (HAP), healthcare-associated (HCAP) and ventilator-associated (VAP) pneumonia. Methods: A systematic review and meta-analysis was carried out retrieving both experimental and observational studies. Results: A total of 2364 records was found and 14 manuscripts were finally considered eligible. The pooled efficacy/effectiveness was 81.2% (I2: 1.2%) in all types of pneumonia. The pooled relative risk of clinical cure was 1.1 (I2: 0.0%). The success rate was higher than 70% for infections caused by S. pneumoniae and S. aureus, including MDR pathogens. Conclusions: Ceftaroline fosamil showed a high efficacy/effectiveness in patients with any type of pneumonia with a good safety profile.

Original languageEnglish
Article number205
JournalRespiratory Research
Volume19
Issue number1
DOIs
Publication statusPublished - Oct 23 2018

Fingerprint

Health Services
Meta-Analysis
Pneumonia
Public Health
Health
Ventilator-Associated Pneumonia
Manuscripts
Infection
Pharmaceutical Preparations
Observational Studies
Anti-Bacterial Agents
Delivery of Health Care
Safety
PPI-0903

Keywords

  • CAP
  • HAP
  • HCAP
  • MRSA
  • Safety
  • Stewardship
  • VAP

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{15364b96d12b40ad9b569b8611c47d52,
title = "Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: A systematic review and meta-analysis 11 Medical and Health Sciences 1117 Public Health and Health Services",
abstract = "Background: Pneumonia is a relevant clinical and public health issue worldwide frequently associated with infections caused by Multi-Drug Resistant (MDR) pathogens. Ceftaroline fosamil is a promising new antibiotics with broad-spectrum bacterial activity. The aim of this systematic review and meta-analysis is to assess the efficacy and the effectiveness of ceftaroline fosamil in community-acquired (CAP), hospital-acquired (HAP), healthcare-associated (HCAP) and ventilator-associated (VAP) pneumonia. Methods: A systematic review and meta-analysis was carried out retrieving both experimental and observational studies. Results: A total of 2364 records was found and 14 manuscripts were finally considered eligible. The pooled efficacy/effectiveness was 81.2{\%} (I2: 1.2{\%}) in all types of pneumonia. The pooled relative risk of clinical cure was 1.1 (I2: 0.0{\%}). The success rate was higher than 70{\%} for infections caused by S. pneumoniae and S. aureus, including MDR pathogens. Conclusions: Ceftaroline fosamil showed a high efficacy/effectiveness in patients with any type of pneumonia with a good safety profile.",
keywords = "CAP, HAP, HCAP, MRSA, Safety, Stewardship, VAP",
author = "Giovanni Sotgiu and Stefano Aliberti and Andrea Gramegna and Marco Mantero and {Di Pasquale}, Marta and Federica Trogu and Laura Saderi and Francesco Blasi",
year = "2018",
month = "10",
day = "23",
doi = "10.1186/s12931-018-0905-x",
language = "English",
volume = "19",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia

T2 - A systematic review and meta-analysis 11 Medical and Health Sciences 1117 Public Health and Health Services

AU - Sotgiu, Giovanni

AU - Aliberti, Stefano

AU - Gramegna, Andrea

AU - Mantero, Marco

AU - Di Pasquale, Marta

AU - Trogu, Federica

AU - Saderi, Laura

AU - Blasi, Francesco

PY - 2018/10/23

Y1 - 2018/10/23

N2 - Background: Pneumonia is a relevant clinical and public health issue worldwide frequently associated with infections caused by Multi-Drug Resistant (MDR) pathogens. Ceftaroline fosamil is a promising new antibiotics with broad-spectrum bacterial activity. The aim of this systematic review and meta-analysis is to assess the efficacy and the effectiveness of ceftaroline fosamil in community-acquired (CAP), hospital-acquired (HAP), healthcare-associated (HCAP) and ventilator-associated (VAP) pneumonia. Methods: A systematic review and meta-analysis was carried out retrieving both experimental and observational studies. Results: A total of 2364 records was found and 14 manuscripts were finally considered eligible. The pooled efficacy/effectiveness was 81.2% (I2: 1.2%) in all types of pneumonia. The pooled relative risk of clinical cure was 1.1 (I2: 0.0%). The success rate was higher than 70% for infections caused by S. pneumoniae and S. aureus, including MDR pathogens. Conclusions: Ceftaroline fosamil showed a high efficacy/effectiveness in patients with any type of pneumonia with a good safety profile.

AB - Background: Pneumonia is a relevant clinical and public health issue worldwide frequently associated with infections caused by Multi-Drug Resistant (MDR) pathogens. Ceftaroline fosamil is a promising new antibiotics with broad-spectrum bacterial activity. The aim of this systematic review and meta-analysis is to assess the efficacy and the effectiveness of ceftaroline fosamil in community-acquired (CAP), hospital-acquired (HAP), healthcare-associated (HCAP) and ventilator-associated (VAP) pneumonia. Methods: A systematic review and meta-analysis was carried out retrieving both experimental and observational studies. Results: A total of 2364 records was found and 14 manuscripts were finally considered eligible. The pooled efficacy/effectiveness was 81.2% (I2: 1.2%) in all types of pneumonia. The pooled relative risk of clinical cure was 1.1 (I2: 0.0%). The success rate was higher than 70% for infections caused by S. pneumoniae and S. aureus, including MDR pathogens. Conclusions: Ceftaroline fosamil showed a high efficacy/effectiveness in patients with any type of pneumonia with a good safety profile.

KW - CAP

KW - HAP

KW - HCAP

KW - MRSA

KW - Safety

KW - Stewardship

KW - VAP

UR - http://www.scopus.com/inward/record.url?scp=85055431196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055431196&partnerID=8YFLogxK

U2 - 10.1186/s12931-018-0905-x

DO - 10.1186/s12931-018-0905-x

M3 - Article

C2 - 30352588

AN - SCOPUS:85055431196

VL - 19

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

IS - 1

M1 - 205

ER -